Browse the evidence

CRDs improved hepatic stress (GGT: SMD = -6.08 U/L) and renal function (UACR: SMD = -0.19).

CRDs may be beneficial for improving liver and kidney health in adults.

Gross variability in resistance training outcomes often reflects confounding sources of within-participant variation rather than true inter-individual differences.

Practitioners should be cautious in interpreting variability in training outcomes.

Retatrutide shows additional benefits for metabolic comorbidities such as NASH and cardiovascular disease.

Retatrutide may help manage obesity-related metabolic conditions.

Higher percentage body fat (PBF) is associated with successful weight reduction in both male (OR = 3.990) and female (OR = 2.266) patients.

Monitoring body fat percentage may help predict weight loss success in patients undergoing GLP-1RA treatment.

Exenatide combined with Metformin improved 2-hour oral glucose tolerance test (OGTT) values by a mean difference of -1.78 (p < 0.001).

The combination therapy may enhance glucose tolerance in women with PCOS.

MRs significantly reduce glycated hemoglobin (HbA1c) levels by 0.24%.

Using meal replacements can lead to better long-term glucose management.

MRs cause a greater decrease in FBS, insulin, and HOMA-IR in individuals over 50 years old compared to those aged 50 years or younger.

Older adults may benefit more from meal replacements in terms of glucose metabolism.

Patients taking GLP-1 RAs had superior nutritional status compared to postbariatric patients, indicated by higher albumin and prealbumin levels.

Improved nutritional status in GLP-1 RA patients may enhance surgical outcomes and recovery.

BHB supplementation led to a reduction in LDL cholesterol in the BHB group.

BHB supplementation may improve lipid profiles in overweight and obese individuals.

GLP-1RAs improve blood pressure regulation and lipid metabolism.

Incorporating GLP-1RAs may enhance management of blood pressure and lipid levels in diabetic patients.

A thorough preoperative evaluation is essential to optimize outcomes and minimize risks for body contouring procedures after significant weight loss.

Practitioners should ensure thorough evaluations before body contouring surgeries.

Semaglutide represents a practice-changing therapy that addresses core pathophysiological drivers of ASCVD and HFpEF through integrated modulation of adiposity and metabolic dysfunction.

Clinicians should consider semaglutide as a key treatment option for managing ASCVD and HFpEF.

Metabolic and bariatric surgery (MBS) is the most effective long-term treatment for severe obesity and its associated comorbidities.

MBS should be considered as a primary treatment option for patients with severe obesity.

MBS is associated with improved glycemic and metabolic control, lower apnea burden, reduced risk of major adverse cardiovascular events, and improved overall survival.

MBS can significantly improve health outcomes for patients with severe obesity.

Responders to the PF regimen exhibited enhanced metabolic flexibility compared to non-responders.

Personalized dietary interventions may enhance metabolic flexibility in patients with T2D.

Higher consumption of animal-based foods may mitigate the risk of elevated TyG among women.

Encouraging a balanced intake of animal-based foods may be beneficial for women at risk of elevated TyG.

Both 0839 and 0833 improved metabolic parameters and reduced body weight primarily by fat mass reduction.

These compounds may be effective for fat loss and improving metabolic health.

Optimal obesity management requires a systematic assessment that extends beyond body mass index (BMI).

Clinicians should incorporate comprehensive assessments in obesity management.

Obesity is a significant pathogenic factor for multiple chronic conditions and ranks as the sixth leading risk factor for mortality and disability nationwide.

Healthcare practitioners should recognize obesity as a critical factor in managing chronic diseases.

Dual agonists represent a transformative therapeutic class for metabolic disease management.

Clinicians should consider dual agonists as a key component in the management of metabolic diseases.

RYGB showed significantly greater weight loss than SG at both 12 months (30.3% vs. 25.4%; p < 0.001) and 24 months (26.3% vs. 21.4%; p < 0.001).

Practitioners should consider RYGB for patients seeking greater weight loss outcomes.

Metabolic bariatric surgery is associated with improvements in weight, AHI, upper airway collapsibility, and loop gain.

Practitioners may consider metabolic bariatric surgery as a treatment option for patients with OSA to improve various physiological traits.

Key secondary endpoints include categorical weight-loss thresholds, changes in anthropometric and cardiometabolic measures, and comprehensive safety and tolerability assessments.

The trial will assess various health metrics alongside weight loss to evaluate overall impact.

Obesity without metabolic abnormalities increases the risk of atherosclerotic cardiovascular disease (ASCVD) by 46% in men and 34% in women compared to those with normal BMI.

Practitioners should recognize that obesity, even without metabolic abnormalities, poses significant cardiovascular risks.